These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

375 related items for PubMed ID: 30562907

  • 1. Impact of Disease Duration in Effectiveness of Treatment with Levodopa-Carbidopa Intestinal Gel and Factors Leading to Discontinuation.
    Regidor I, Santos-García D, Catalán MIJ, Puente V, Valldeoriola F, Grandas F, Mir P, Parra JC, Arbelo JM.
    J Parkinsons Dis; 2019; 9(1):173-182. PubMed ID: 30562907
    [Abstract] [Full Text] [Related]

  • 2. Levodopa-Carbidopa Intestinal Gel Monotherapy: GLORIA Registry Demographics, Efficacy, and Safety.
    Poewe W, Bergmann L, Kukreja P, Robieson WZ, Antonini A.
    J Parkinsons Dis; 2019; 9(3):531-541. PubMed ID: 31282424
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Rescue levodopa-carbidopa intestinal gel (LCIG) therapy in Parkinson's disease patients with suboptimal response to deep brain stimulation.
    Elkouzi A, Ramirez-Zamora A, Zeilman P, Barabas M, Eisinger RS, Malaty IA, Okun MS, Almeida L.
    Ann Clin Transl Neurol; 2019 Oct; 6(10):1989-1995. PubMed ID: 31518070
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Levodopa/carbidopa intestinal gel infusion and weight loss in Parkinson's disease.
    Fabbri M, Zibetti M, Beccaria L, Merola A, Romagnolo A, Montanaro E, Ferreira JJ, Palermo S, Lopiano L.
    Eur J Neurol; 2019 Mar; 26(3):490-496. PubMed ID: 30347489
    [Abstract] [Full Text] [Related]

  • 13. Levodopa-carbidopa intestinal gel in advanced Parkinson's disease open-label study: interim results.
    Fernandez HH, Vanagunas A, Odin P, Espay AJ, Hauser RA, Standaert DG, Chatamra K, Benesh J, Pritchett Y, Hass SL, Lenz RA.
    Parkinsonism Relat Disord; 2013 Mar; 19(3):339-45. PubMed ID: 23287001
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Levodopa-carbidopa intestinal gel in advanced Parkinson's: Final results of the GLORIA registry.
    Antonini A, Poewe W, Chaudhuri KR, Jech R, Pickut B, Pirtošek Z, Szasz J, Valldeoriola F, Winkler C, Bergmann L, Yegin A, Onuk K, Barch D, Odin P, GLORIA study co-investigators.
    Parkinsonism Relat Disord; 2017 Dec; 45():13-20. PubMed ID: 29037498
    [Abstract] [Full Text] [Related]

  • 16. Predictors of Time to Discontinuation of Levodopa-Carbidopa Intestinal Gel Infusion: A Retrospective Cohort Study.
    Moes HR, Groenendal-Laurensse JWMJ, Drent M, Tissingh G, van Laar T.
    J Parkinsons Dis; 2020 Dec; 10(3):935-944. PubMed ID: 32675420
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Dopamine agonist withdrawal syndrome (DAWS) symptoms in Parkinson's disease patients treated with levodopa-carbidopa intestinal gel infusion.
    Solla P, Fasano A, Cannas A, Mulas CS, Marrosu MG, Lang AE, Marrosu F.
    Parkinsonism Relat Disord; 2015 Aug; 21(8):968-71. PubMed ID: 26071817
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.